Kestra Advisory Services’s Corbus Pharmaceuticals CRBP Stock Holding History

Kestra Advisory Services’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-560	Closed	-$1.86K	–	2119
2022 Q4	$1.86K	Buy	560 +52	+10%	+$200	﹤0.01%	2247
2022 Q3	$3K	Hold	508	–	–	﹤0.01%	2097
2022 Q2	$4K	Sell	508 -17	-3%	-$164	﹤0.01%	2123
2022 Q1	$8K	Sell	525 -117	-18%	-$1.55K	﹤0.01%	1990
2021 Q4	$12K	Sell	642 -144	-18%	-$3.9K	﹤0.01%	2002
2021 Q3	$24K	Buy	786 +66	+9%	+$2.6K	﹤0.01%	2100
2021 Q2	$40K	Sell	720 -66	-8%	-$3.66K	﹤0.01%	1984
2021 Q1	$46K	Sell	786 -139	-15%	-$9.14K	﹤0.01%	1830
2020 Q4	$36K	Sell	925 -221	-19%	-$8.26K	﹤0.01%	1828
2020 Q3	$62K	Buy	+1,146	New	+$208K	﹤0.01%	1377

Other funds holding CRBP

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Kestra Advisory Services's CRBP Position: Q1 2023 in Review

Kestra Advisory Services sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 560 shares — an estimated $1.86K sold.

Kestra Advisory Services first reported a position in CRBP in Q3 2020 and held it in 10 quarters. The position peaked at $62K in Q3 2020. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

Kestra Advisory Services reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Kestra Advisory Services sold 560 Corbus Pharmaceuticals shares in Q1 2023, an estimated $1.86K.
Kestra Advisory Services first reported a position in Corbus Pharmaceuticals in Q3 2020 and held it in 10 quarters.
Kestra Advisory Services's Corbus Pharmaceuticals position peaked at $62K in Q3 2020.
30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on Kestra Advisory Services's 13F filing for Q1 2023, filed 12 May 2023.